Table 3.
Comparison of initial antimicrobial agents use in patients with non-ventilator and ventilator-associated hospital-acquired pneumonia
| Main agents used |
Group, n (%) |
p Value | |
|---|---|---|---|
| Non-ventilator associated (n = 48) | Ventilator-associated (n = 96) | ||
| Anti-pseudomonal penicillinsa |
5 (10.4) |
10 (10.4) |
1.000 |
| Anti-pseudomonal cephalosporinsb |
12 (25.0) |
18 (18.8) |
0.514 |
| Anti-pseudomonal fluoroquinolonesc |
4 (8.3) |
4 (4.2) |
0.441 |
| Anti-pseudomonal carbapenemsd |
14 (29.2) |
29 (30.2) |
1.000 |
| Ampicillin/sulbactam or sulbactam |
5 (10.4) |
13 (13.5) |
0.789 |
| Non-anti-pseudomonal β-lactamasee |
6 (12.5) |
16 (16.7) |
0.682 |
| Miscellaneousf | 2 (4.2) | 6 (6.3) | 0.719 |
aIncluding piperacillin, piperacillin/tazobactam, and ticarcillin/clavulanate.
bIncluding cefoperazone, ceftazidime, cefepime, and cefpirome.
cIncluding ciprofloxacin and levofloxacin.
dIncluding imipenem and meropenem.
eIncluding penicillin, amoxicillin/clavulanate, cefazolin, cefuroxime, cefotaxime, cefmetazole, and flomoxef.
fIncluding teicoplanin or clindamycin plus amikacin.